Hympavzi (marstacimab-hncq) — Medica

Hemophilia A without Factor VIII inhibitors

Initial criteria

age ≥ 12 years
using Hympavzi for routine prophylaxis to prevent or reduce the frequency of bleeding episodes
has moderately severe to severe hemophilia A as evidenced by baseline Factor VIII level ≤ 2% (without Factor VIII replacement therapy)
EITHER (a) Factor VIII inhibitor titer testing performed within the past 30 days AND inhibitor titer < 1.0 Bethesda units/mL OR (b) has not received Factor VIII therapy in the past
prophylactic use of Factor VIII products will be discontinued (use for breakthrough bleeding allowed)
prescribed by or in consultation with a hemophilia specialist

using Hympavzi for routine prophylaxis to prevent or reduce the frequency of bleeding episodes
prophylactic use of Factor VIII products will not occur while receiving Hympavzi (use for breakthrough bleeding allowed)
prescribed by or in consultation with a hemophilia specialist
patient experienced a beneficial response to therapy (e.g., reduction in bleeding events, severity, or spontaneous bleeds)

1 year